. home.aspx



ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech

October 14, 2019 / Richard Staines

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that allows scientists to see inside tumours, and monitor whether immunotherapies are taking effect. ImaginAb’s imaging technology targets and visualises CD8+ T cells that are called in to attack tumours by immunotherapies. The company’s ‘Minibody’ platform can assess the immunological status of each cancer lesion within a patient, potentially enabling treatment to be tailored quickly and specifically to the needs of a patient. Under the terms of the agreement, the collaborators will help guide a current ImaginAb-sponsored clinical trial that aims to evaluate the utility and value of CD8 ImmunoPET in immuno-oncology drug development. In return, the collaborators will gain early access to clinical and imaging data, and collectively contribute to the post-trial data analysis. The agreement builds on an impressive list of collaborators tha...